Skip to main content
. 2024 Jun 28;27(8):110413. doi: 10.1016/j.isci.2024.110413

Figure 9.

Figure 9

The expression and CpG methylation of the PCDHB4 as prognostic markers in LUSC

(A) Kaplan-Meier curves of OS (left panel) and PFS (right panel) of LUSC patients with low and high PCDHB4 expression.

(B) Kaplan-Meier curves of the PFS of LUSC patients with low and high PCDHB4 expression, who were treated with platinum-based chemotherapy.

(C) Boxplot showing the expression of PCDHB4 in LUSC patients who were responsive or non-responsive to platinum-based chemotherapy. The differences between groups were analyzed by Wilcoxon test and p < 0.05 was considered statistically significant.

(D) Kaplan-Meier curves of OS (left panel) and PFS (right panel) of LUSC patients with low and high methylation levels of the PCDHB4 CpG site (cg24918705).

(E) Kaplan-Meier curves of OS (left panel) and PFS (right panel) of LUSC patients with low and high methylation levels of PCDHB4 CpG site (cg24918705), who were treated with platinum-based chemotherapy.

(F) Boxplot showing the methylation level of PCDHB4 CpG sites in LUSC patients who were responsive or non-responsive to platinum-based chemotherapy. The differences between groups were analyzed by Wilcoxon test and p < 0.05 was considered statistically significant.